Subcostal Temporary Extravascular Pacing IV (STEP IV) Study — STEP IV  

Conduction Defect Clinical Trial

Official title: Subcostal Temporary Extravascular Pacing IV (STEP IV) Study

Status Completed

Clinical Trial Summary

The STEP IV Study is a prospective, single-center, non-randomized, single-arm study without concurrent or historical controls. The objective of the study is to generate safety and performance data of the latest AtaCor EV Temporary Pacing Lead System to support the development of a future pivotal study with an indication limited to a maximum of 7 days.

Clinical Trial Description

The primary safety objective is freedom from Adverse Device Effects (ADE). The primary performance objective is summary statistics for pacing capture threshold, impedance, and sensed R-wave amplitude with the StealthTrac Lead from insertion through removal. One (1) Investigational Site in Paraguay will participate with up to 16 subjects enrolled in the study. Subjects indicated for a closed-chest cardiac invasive procedure will be eligible for participation. Subjects undergoing a qualifying index procedure will have a Model AC-1013 StealthTrac Lead inserted and evaluated over the follow-up period (up to 7 days post procedure). Study participation requires 2 to 7 days with the Study Lead inserted. Following Study Lead removal, a final follow-up will be performed 27-33 days after lead insertion to assess for any latent Adverse Events. Subjects remain enrolled until completion of the 30-Day Follow Up. The maximum duration for study participation is 33 days. The Study is expected to last up to 3 months after first enrollment: Enrollment and follow-up (1 month) and final report (2 months). ;

Related Conditions & MeSH terms

• Conduction Defect

• NCT number: NCT05457673
• Study type: Interventional
• Source: AtaCor Medical, Inc.
• Status: Completed
• Phase: N/A
• Start date: August 17, 2022
• Completion date: October 20, 2022